AIM: To examine the influence of the black currant anthocyanins (BCACs) on the disease progression of open-angle glaucoma (OAG), a randomized, placebo-controlled, double-masked trial was made in 38 patients with OAG treated by antiglaucoma drops. METHODS:BCACs (50 mg/day, n = 19) or their placebos (n = 19) were orally administered once daily for a 24-month period. Systemic blood pressure, pulse rates, intraocular pressure (IOP), ocular blood circulation by laser-speckle flowgraphy, and Humphrey visual fieldmean deviation (MD) were measured during the 24-month period. RESULTS: As a main outcome measurement, we evaluated the difference between the groups in MD deterioration in the eye with a better MD from the trial's baseline through 24 months. A statistically significant difference was observed between the treatment groups in mean change from baseline in MD 24 months after therapy (p = 0.039, unpaired t test). Upon administration of BCACs, the ocular blood flows during the 24-month observational period increased in comparison with placebo-treated patients. However, no significant changes were observed in systemic and ocular conditions including IOP during the 24-month period. CONCLUSIONS: Our results suggest that oral administration of BCACs may be a safe and promising supplement for patients with OAG in addition to antiglaucoma medication.
RCT Entities:
AIM: To examine the influence of the black currant anthocyanins (BCACs) on the disease progression of open-angle glaucoma (OAG), a randomized, placebo-controlled, double-masked trial was made in 38 patients with OAG treated by antiglaucoma drops. METHODS:BCACs (50 mg/day, n = 19) or their placebos (n = 19) were orally administered once daily for a 24-month period. Systemic blood pressure, pulse rates, intraocular pressure (IOP), ocular blood circulation by laser-speckle flowgraphy, and Humphrey visual field mean deviation (MD) were measured during the 24-month period. RESULTS: As a main outcome measurement, we evaluated the difference between the groups in MD deterioration in the eye with a better MD from the trial's baseline through 24 months. A statistically significant difference was observed between the treatment groups in mean change from baseline in MD 24 months after therapy (p = 0.039, unpaired t test). Upon administration of BCACs, the ocular blood flows during the 24-month observational period increased in comparison with placebo-treated patients. However, no significant changes were observed in systemic and ocular conditions including IOP during the 24-month period. CONCLUSIONS: Our results suggest that oral administration of BCACs may be a safe and promising supplement for patients with OAG in addition to antiglaucoma medication.
Authors: Jae H Kang; Kerry L Ivey; Tahani Boumenna; Bernard Rosner; Janey L Wiggs; Louis R Pasquale Journal: Acta Ophthalmol Date: 2018-03-14 Impact factor: 3.761
Authors: James R Tribble; Flora Hui; Melissa Jöe; Katharina Bell; Vicki Chrysostomou; Jonathan G Crowston; Pete A Williams Journal: Cells Date: 2021-02-01 Impact factor: 6.600
Authors: María-Teresa García-Conesa; Karen Chambers; Emilie Combet; Paula Pinto; Mar Garcia-Aloy; Cristina Andrés-Lacueva; Sonia de Pascual-Teresa; Pedro Mena; Alekxandra Konic Ristic; Wendy J Hollands; Paul A Kroon; Ana Rodríguez-Mateos; Geoffrey Istas; Christos A Kontogiorgis; Dilip K Rai; Eileen R Gibney; Christine Morand; Juan Carlos Espín; Antonio González-Sarrías Journal: Int J Mol Sci Date: 2018-02-28 Impact factor: 5.923
Authors: Mar Valero-Vello; Cristina Peris-Martínez; José J García-Medina; Silvia M Sanz-González; Ana I Ramírez; José A Fernández-Albarral; David Galarreta-Mira; Vicente Zanón-Moreno; Ricardo P Casaroli-Marano; María D Pinazo-Duran Journal: Foods Date: 2021-05-28